Full Press Release Details
Index to Unaudited Interim Condensed Consolidated
Financial Statements
| Unaudited condensed consolidated statements of comprehensive loss | 2 |
| Condensed consolidated statements of financial position as of December 31, 2016 (audited) and September 30, 2017 (unaudited) | 3 |
| Unaudited condensed consolidated statements of changes in equity | 4 |
| Unaudited condensed consolidated statements of cash flows | 5 |
| Notes to the unaudited interim condensed consolidated statements | 6 |
consolidated statements of comprehensive loss
| For the three months | For the nine months | |||||||||||||||||||
| ended September 30, | ended September 30, | |||||||||||||||||||
| in thousand | Note* | 2016 | 2017 | 2016 | 2017 | |||||||||||||||
| Other income and expenses (net) | 54 | 81 | 139 | 111 | ||||||||||||||||
| Research and development expenses | (1,059 | ) | (2,606 | ) | (2,476 | ) | (8,108 | ) | ||||||||||||
| General and administrative expenses | (528 | ) | (691 | ) | (1,052 | ) | (2,037 | ) | ||||||||||||
| Loss before interest and income taxes | (1,533 | ) | (3,216 | ) | (3,389 | ) | (10,034 | ) | ||||||||||||
| Finance costs (net) | 5 | (623 | ) | (841 | ) | (1,189 | ) | (2,496 | ) | |||||||||||
| Loss for the period | (2,156 | ) | (4,057 | ) | (4,578 | ) | (12,530 | ) | ||||||||||||
| Other comprehensive income | ||||||||||||||||||||
| Items that may be reclassified subsequently | ||||||||||||||||||||
| to profit or loss: | ||||||||||||||||||||
| Exchange differences on translating | ||||||||||||||||||||
| foreign operations | 0 | 2 | 0 | 0 | ||||||||||||||||
| Other comprehensive income for the period | 0 | 2 | 0 | 0 | ||||||||||||||||
| Total comprehensive loss | (2,156 | ) | (4,055 | ) | (4,578 | ) | (12,530 | ) | ||||||||||||
| Loss per common share in (basic/diluted) | (77 | ) | (144 | ) | (163 | ) | (445 | ) |
The notes are an integral part of these consolidated financial statements.
Condensed consolidated
statements of financial position
as of December 31, 2016 and September 30, 2017
| in thousand | Note* | December 31, 2016 | September 30, 2017 | |||||||||
| unaudited | ||||||||||||
| ASSETS | ||||||||||||
| Non-current assets | ||||||||||||
| Intangible assets | 5 | 22 | ||||||||||
| Laboratory and office equipment | 131 | 149 | ||||||||||
| Financial assets | 1 | 19 | ||||||||||
| Total non-current assets | 137 | 190 | ||||||||||
| Current assets | ||||||||||||
| Other assets | 3 | 264 | 1,734 | |||||||||
| Cash and cash equivalents | 29,117 | 22,086 | ||||||||||
| Total current assets | 29,381 | 23,820 | ||||||||||
| Total assets | 29,518 | 24,010 | ||||||||||
| EQUITY AND LIABILITIES | ||||||||||||
| Equity | ||||||||||||
| Issued capital | 31 | 31 | ||||||||||
| Other reserves | 4 | 1,685 | 3,756 | |||||||||
| Accumulated deficit | (27,055 | ) | (39,585 | ) | ||||||||
| Own shares | (350 | ) | (350 | ) | ||||||||
| Total equity | (25,689 | ) | (36,148 | ) | ||||||||
| Non-current liabilities | ||||||||||||
| Preferred shares | 5 | 53,440 | 57,428 | |||||||||
| Deferred income | 19 | 16 | ||||||||||
| Provisions | 2 | 2 | ||||||||||
| Total non-current liabilities | 53,461 | 57,446 | ||||||||||
| Current liabilities | ||||||||||||
| Trade payables | 1,534 | 2,520 | ||||||||||
| Other liabilities | 212 | 192 | ||||||||||
| Total current liabilities | 1,746 | 2,712 | ||||||||||
| Total equity and liabilities | 29,518 | 24,010 |
The notes are an integral part of these consolidated financial statements.
consolidated statements of changes in equity
| Other reserves | |||||||||||||
| currency | share | Accumu- | |||||||||||
| Issued | trans- | based | lated | Own | Total | ||||||||
| in thousand | capital | lation | payments | deficit | shares | equity | |||||||
| Balance as of January 1, 2016 | 31 | 9 | 807 | (18,116) | (350) | (17,619) | |||||||
| Comprehensive loss | |||||||||||||
| Loss for the period | 0 | 0 | 0 | (4,578) | 0 | (4,578) | |||||||
| Other comprehensive income | |||||||||||||
| Exchange differences on | |||||||||||||
| translating foreign operations | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
| Total comprehensive loss | 0 | 0 | 0 | (4,578) | 0 | (4,578) | |||||||
| Recognition of equity-settled | |||||||||||||
| share-based payments | 0 | 0 | 207 | 0 | 0 | 207 | |||||||
| Balance as of September 30, 2016 | 31 | 9 | 1,014 | (22,694) | (350) | (21,990) | |||||||
| Balance as of January 1, 2017 | 31 | 10 | 1,675 | (27,055) | (350) | (25,689) | |||||||
| Comprehensive loss | |||||||||||||
| Loss for the period | 0 | 0 | 0 | (12,530) | 0 | (12,530) | |||||||
| Other comprehensive income | |||||||||||||
| Exchange differences on | |||||||||||||
| translating foreign operations | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
| Total comprehensive loss | 0 | 0 | 0 | (12,530) | 0 | (12,530) | |||||||
| Closure of InflaRx Inc. | 0 | (10) | 0 | 0 | 0 | (10) | |||||||
| Recognition of equity-settled | |||||||||||||
| share-based payments | 0 | 0 | 2,081 | 0 | 0 | 2,081 | |||||||
| Balance as of September 30, 2017 | 31 | 0 | 3,756 | ( 39,585 ) | (350) | (36,148) |
The notes are an integral part of these consolidated financial statements.
consolidated statements of cash flows
| For the nine months | ||||||||
| ended September 30, | ||||||||
| in thousand | 2016 | 2017 | ||||||
| Cash flow from operating activities | ||||||||
| Loss for the period | (4,578 | ) | (12,530 | ) | ||||
| Adjustments for the period: | ||||||||
| - Depreciation and amortization | 24 | 53 | ||||||
| - Expenses recognized in respect of equity-settled share-based payments | 207 | 2,081 | ||||||
| - Finance costs (net) | 1,182 | 2,496 | ||||||
| (3,165 | ) | (7,900 | ) | |||||
| Change in other assets | 31 | (1,470 | ) | |||||
| Change in trade and other payables and deferred income | (29 | ) | 963 | |||||
| Interest paid (received) | 0 | (18 | ) | |||||
| Net cash used in operating activities | (3,163 | ) | (8,425 | ) | ||||
| Cash flow from investing activities | ||||||||
| Purchase of intangible assets | 0 | (21 | ) | |||||
| Purchase of leasehold improvements and equipment | (8 | ) | (67 | ) | ||||
| Cash paid for financial assets | 0 | (18 | ) | |||||
| Net cash used in investing activities | (8 | ) | (106 | ) | ||||
| Cash flow from financing activities | ||||||||
| Proceeds from issuance of preferred shares | 30,993 | 1,500 | ||||||
| Share issue costs paid | (95 | ) | 0 | |||||
| Net cash generated from financing activities | 30,898 | 1,500 | ||||||
| Net changes to cash and cash equivalents | 27,727 | (7,031 | ) | |||||
| Cash and cash equivalents at the beginning of the year | 3,302 | 29,117 | ||||||
| Exchange gains on cash and cash equivalents | 0 | 0 | ||||||
| Cash and cash equivalents at the end of the year | 31,029 | 22,086 |
The notes are an integral part of these consolidated financial statements.
Notes to the unaudited interim condensed
consolidated financial statements
InflaRx GmbH ("InflaRx" or the
"Company") is a German private limited liability company formed in 2007 and is registered in the Commercial Register
of the Jena local court HRB 502149. The Company's registered office is at Winzerlaer Stra e
2 in 07745 Jena, Germany.
InflaRx is a clinical-stage biopharmaceutical
company focused on applying its proprietary technology to discover and develop first-in-class, potent and specific inhibitors of
the complement activation factor known as C5a.
In November 2017, the Company executed a
corporate reorganization whereby InflaRx N.V., a Dutch public company with limited liability (naamloze vennootschap) with
its corporate seat in Amsterdam, the Netherlands, became the holding company for the Company in connection with the initial public
offering of InflaRx N.V. and the listing of its common shares on the NASDAQ Global Select Market. For note disclosures describing
the corporate reorganization and the initial public offering, refer to "note (7) Significant Events After the Reporting Date."
The condensed consolidated interim financial
statements (the "interim financial statements") as of and for the three and nine months ended September 30, 2017 presented
herein are reported by the Company and do not include the effects of the corporate reorganization, which occurred in the fourth
quarter of 2017 as described in further detail in "note (7) Significant Events After the Reporting Date." These interim
financial statements comprise the Company and, until September 12, 2017, its wholly owned subsidiary, InflaRx Inc., Ann Arbor,
Michigan, USA (together, the "Group"), which was dissolved on September 12, 2017. The consolidated financial statements
of InflaRx and InflaRx N.V., together with any of its future consolidated subsidiaries, as of and for the year ended December 31,
2017 and for each reporting period going forward, will be reported by InflaRx N.V.
The interim financial statements of InflaRx
for the three and nine months ended September 30, 2017 and 2016 have been prepared in accordance with IAS 34 Interim Financial
Reporting. The interim financial statements do not include all the information and disclosures required in the annual financial
statements, and should be read in conjunction with the Group's annual consolidated financial statements as at December 31,
The interim financial statements were authorized
for issuance by management on December 14, 2017.
The preparation of the interim financial
statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application
of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these
estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized
in the period in which the estimates are revised and in any future periods affected.
In preparing these interim financial statements,
the critical judgments made by management in applying the Group's accounting policies and the key accounting estimates were
the same as those that applied to the annual consolidated financial statements as at and for the year ended December 31, 2016.
These interim financial statements are presented
in thousands of Euro, which is also the Group's functional currency. All financial information presented in Euro has been
rounded to the nearest thousand (abbreviated ) or million (abbreviated million).
The accounting policies applied by the Group
in these interim financial statements are the same as those applied by the Group in its consolidated financial statements as at
and for the year ended December 31, 2016.
New standards and interpretations applied
The following amendments to standards and
new or amended interpretations are effective for annual periods beginning on or before January 1, 2017, and will be applied in
preparing the annual financial statements for the year 2017:
| Standard/Interpretation | Effective Date 1 |
| Amendments to IAS 7 Disclosure Initiative | January 1, 2017 |
1 Shall apply for periods
beginning on or after the date shown in the effective date column.
New standards and interpretations not
The following standards, amendments to standards
and interpretations are effective for annual periods beginning after December 31, 2017, and have not been applied in preparing
these consolidated financial statements.
| Standard/Interpretation | Effective Date 1 |
| IFRS 15 Revenue from Contracts with Customers | January 1, 2018 |
| IFRS 9 Financial Instruments (2014) | January 1, 2018 |
| Clarifications to IFRS 15 Revenue from Contracts with Customers | January 1, 2018 |
| Amendments to IFRS 2: Classification and Measurement of Share- | |
| based Payment Transactions | January 1, 2018 |
| Annual Improvements to IFRS Standards 2014-2016 Cycle | January 1, 2018 |
| IFRS 16 Leases | January 1, 2019 |
1 Shall apply for periods
beginning on or after the date shown in the effective date column.
The Group is assessing the potential impact
that IFRS 9 could have on its consolidated financial statements. The new accounting standard IFRS 15 is currently not applicable
to InflaRx because no revenue will be generated for the foreseeable future by the Group.
InflaRx will adopt IFRS 9 initially on January
1, 2018. Management will apply the new standard retrospectively in accordance with IAS 8. In addition, management has elected to
not restate comparative information as permitted by IFRS 9. At the date of initial application, InflaRx will record any difference
between previous carrying amounts and those determined under IFRS 9 in opening retained earnings.
InflaRx does not expect any actual impact
on its financial statements for fiscal year 2018 from the adoption of IFRS 9. InflaRx currently holds other assets, trade and other
payables. InflaRx does not hold and expects not to hold in 2018 any other financial instruments, including equity instruments,
derivatives or financial liabilities, that would warrant a new classification or revised measurement under IFRS 9. The new standard
will nevertheless require InflaRx to revise its accounting processes and internal controls related to reporting financial instruments
that InflaRx may hold in the foreseeable future, and these changes are not yet complete. However, InflaRx is continuing to evaluate
the potential impact from IFRS 9.
The other new or amended standards and interpretations
are not expected to have a significant effect on the consolidated financial statements of the Group.
Other assets include prepaid expenses of
1,372 as of September 30, 2017 (as of 31 December 2016: 0) related to the Company's initial public offering.
InflaRx established an equity-settled share-based
payment program in 2016 (the "2016 Plan"). Pursuant to the 2016 Plan, InflaRx granted to its managing directors, certain
executive officers and key employees options to acquire common shares. Each option grant vests on a graded pattern over a period
of 36 months following the initial grant date, with one-twelfth of the options within such grant vesting every three months during
the total vesting period. However, the vesting of options will automatically accelerate upon the occurrence of certain events such
as an initial public offering or an exit event, as defined in the terms of the preferred shares (see note 5). Share based awards,
including options granted under the 2016 Plan, were exchanged for awards exercisable for common shares of InflaRx upon consummation
of the corporate reorganization. See "note (7) Significant Events After the Reporting Date" for further details.
Prior to the initial public offering, InflaRx